Skip to content
- Autier J, et al. Effets secondaires cutanés du sorafenib et du sunitinib. Ann Dermatol Venereol 2008;135:148-53.
- Guillot B, et al. Aspects cliniques et prise en charge des effets secondaires cutanés du récepteur à l’EGF. Ann Dermatol Venereol 2006;133:1017-20.
- Lacouture ME, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114:485-93.
- Mitchell EP, et al. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC). 2009 ASCO annual meeting CRA 4027.
- Robert C, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
- Bachmeyer C, et al. Cutaneous adverse reactions of EGFR (epidermal growth factor receptor)-inhibitors: therapeutic algorithm of the French PROCUR group. Bull Cancer 2013;100(5):417-26.
- Sinha R, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol 2012;167(5):987-94.